NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. It focuses on the treatment of spinal cord injury, traumatic brain injury, and other brain and neurological indications. The company was founded on June 27, 2011 and is headquartered in Bnei-Brak, Israel.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company